AKT1 and neoplasm: Notably, earlier drug studies in RT2 mice targeting c-Myc [26], VEGFA [17,18], and PI3K/Akt/mTOR signaling [60], yielded similar phenotypes of reduced tumor progression and angiogenesis as seen in RT2; R6KO animals.